Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 28 September

Jessica Amir
September 28, 2021

Morning Bell 27 September

Jessica Amir
September 27, 2021

Weekly Wrap 24 September

Jessica Amir
September 24, 2021

Morning Bell 24 September

Sophia Mavridis
September 24, 2021

Morning Bell 23 September

Paulina Peters
September 23, 2021

Morning Bell 22 September

Jessica Amir
September 22, 2021

Morning Bell 21 September

Jessica Amir
September 21, 2021

Morning Bell 20 September

Jessica Amir
September 20, 2021

Weekly Wrap 17 September

Jessica Amir
September 17, 2021

Morning Bell 17 September

Paulina Peters
September 17, 2021

Morning Bel 16 September

Jessica Amir
September 16, 2021

Morning Bell 15 September

Jessica Amir
September 15, 2021